Get latest articles and stories on India at LatestLY. After three long years of Covid-induced turbulence, 2023 saw a semblance of normalcy in the health sector, allowing the government to turn its attention to other important commitments such as the elimination of sickle cell disease and the launch of Ayushman Bhav to ensure optimum delivery of health schemes. India News | Focus Shifts to Healthcare Delivery in 2023 as Covid Stress Eases.
Now, drugs for four of these diseases -Tyrosinemia Type 1, Gaucher's Disease, Wilson's Disease and Dravet-Lennox Gastaut Syndrome – along with sickle cell Anemia have been approved and are being manufactured indigenously
Drugs for four of these diseases -Tyrosinemia Type 1, Gaucher s Disease, Wilson s Disease and Dravet-Lennox Gastaut Syndrome - along with sickle cell Anemia have been approved and are being manufactured indigenously.
Get latest articles and stories on India at LatestLY. Medicines for four rare diseases have become available at drastically cheaper rates as Indian pharma companies are now producing them reducing the reliance on expensive imported formulations, Union Health Ministry officials said on Friday. India News | Medicines for Four Rare Diseases Become Cheaper Due to Domestic Production.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 954,600 shares, a decline of 5.5% from the October 15th total of 1,010,000 shares. Currently, 4.3% of the company’s shares are short sold. Based on an […]